Detail akcie Kairos Pharma Rg online

Business Summary: Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Kairos Pharma Ltd revenues was not reported. Net loss increased from $1.6M to $4.1M. Higher net loss reflects General and administrative - Balancing v increase from $295K to $2M (expense), Research and development increase from $242K to $1.6M (expense), Stock-based Compensation in SGA increase from $34K to $121K (expense).